Historical clx News Stories
Clorox Outlines Fiscal 2027 Organic Sales Growth of 3.5–4.5% at Boston Staples Conference
At the Boston Global Staples Conference (Sept 9), Clorox forecasts fiscal 2027 organic sales growth of 3.5–4.5%, citing operational improvements and health‑hygiene expansion.
Clorox Schedules Presentation at Barclays Global Consumer Staples Conference on Sept. 9
Clorox (CLX) is set to present at the Barclays Global Consumer Staples Conference on September 9, offering a key opportunity to update investors on strategy amid recent market pressure.
Clorox Schedules Fireside Chat at Barclays Conference Following FY26 Results
Clorox is set to appear Sept. 9 at Barclays Global Consumer Staples Conference after reporting FY26 results and raising its dividend.
Clorox Lifts Fiscal 2027 Outlook Following Q4 Beat and GOJO Acquisition
Clorox beat Q4 expectations and raised FY2027 guidance, driven by its April GOJO acquisition and improving demand in health & wellness, according to Reuters.
Barclays Lowers Clorox Price Target Amid Pricing Strategy Concerns
Barclays reduces Clorox's price target to $84 due to pricing strategy concerns.
Clorox Faces Declining Sales and Market Pressure in Q3 FY2026
On April 30, 2026, The Clorox Company reported its third-quarter fiscal year 2026 results, revealing flat net sales and a downward revision of its full-year guidance. This announcement led to a significant decline in the company's stock price, which reached a 52-week low of $88.38.
Clorox's Recent Financial Performance Amidst Industry Challenges
An analysis of Clorox's recent financial results and industry challenges.
Clorox's Recent Financial Performance and Market Challenges
An analysis of Clorox's recent financial results and stock performance.
Clorox's Strategic Acquisition of GOJO Industries and Its Impact on Stock Performance
Clorox's acquisition of GOJO Industries and its effect on stock performance.
Clorox's Strategic Moves Amidst Industry Challenges
Clorox restructures operations and acquires GOJO Industries to bolster growth.
Clorox Cuts FY26 Outlook; Shares Fall 52-Week Low!
Clorox (CLX) slipped to a 52-week low after the company trimmed its FY2026 guidance following a modest quarterly beat. ERP-related disruptions, inventory drawdowns and weakening consumer demand pressured revenue and margins, prompting analyst downgrades and renewed investor scrutiny despite a still-appealing dividend yield.
Clorox Dips to Lows as $1.55B Notes Fuel Strategy
Clorox (CLX) recently traded near multi-year lows while arranging $1.55 billion in senior notes. This article explains the transactions, investor reaction, and near-term implications for valuation, dividends, and strategic flexibility amid cost pressures in the CPG sector.
Clorox Cuts FY26 Guidance; GOJO Strains Margins!!.
Clorox lowered FY26 adjusted EPS guidance and warned of significant margin pressure driven by weaker demand, higher energy and freight costs, ERP-related disruptions, and the short-term integration effects of its GOJO (Purell) acquisition. Shares fell sharply after the guidance cut. While GOJO expands Clorox’s hygiene portfolio, it creates near-term margin dilution and inventory step-up costs; management expects synergies to materialize in later years. Key near-term risks include oil-driven cost headwinds, ERP stabilization, and recovery in underperforming segments such as litter and food.
Clorox Cuts Guidance; Shares Fall to 52-Week Lows!
Clorox reported mixed results: a modest EPS beat but a lowered full-year guidance that sent CLX shares sharply lower. Rising input costs, integration headwinds and sector-wide pricing pressures are weighing on near-term profit expectations.
Clorox Shock: GOJO Deal, Q2 Hits, Stock Signals #1
Clorox closed its GOJO acquisition while navigating ERP disruption and softer Q2 sales; the stock swung on execution risks, mixed guidance, and defensive sector flows.
Clorox Eyes Growth After GOJO Close; Apr 30 Call
Clorox (CLX) closed its $2.25B GOJO acquisition and set April 30 for Q3 FY2026 results—events that materially shift near-term investor focus toward integration execution, margin recovery, and dividend sustainability.
Clorox After GOJO: Earnings, Yield & Valuation Q3!
Clorox completed the GOJO (Purell) acquisition and will report Q3 FY2026 results on April 30. The deal, recent heavy trading, a near-5% dividend yield, and below-median valuation create a mix of near-term integration risk and longer-term upside potential for CLX investors.
Clorox Closes GOJO Deal; Earnings, Dividends React
Clorox completed its acquisition of GOJO (Purell) while reporting mixed Q2 results. Investors responded with elevated trading, a modest stock pullback, and continued interest in Clorox’s attractive dividend. Integration risks, margin volatility, and shifting institutional ownership now shape near-term expectations for CLX.
Clorox Faces Margin Squeeze; GOJO Deal May Rescue.
Clorox (CLX) is under pressure from margin compression and shifting consumer choices, prompting analyst downgrades. Recent company updates — an ERP rollout completion, participation at Citi’s consumer conference, and progress on the GOJO (Purell) acquisition with ~$50M expected synergies — outline a path to mid‑term recovery. Key investor watch items are synergy execution, margin inflection, and planned deleveraging from ~3.6× to ~2.5× by 2027.
Clorox Faces Downgrade; $2.25B Debt for GOJO
Clorox was downgraded by a major analyst amid margin pressure and weakening demand while recent SEC filings show $2.25 billion in new borrowing to finance the GOJO acquisition. The move raises near-term leverage and execution risks even as hygiene exposure could boost long-term growth.